ClinicalTrials.gg
Active, not recruitingNCT05925803DAISYUpdated Nov 16, 2026

Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)

A Phase 3 interventional study of Anifrolumab (blinded) and Placebo (blinded) in Systemic Sclerosis and Scleroderma, sponsored by AstraZeneca. Active, not recruiting at 151 sites in 23 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Updated Nov 16, 20261 site addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
314
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 165 studies in Scleroderma, Systemic with a site in United States — 40 open to participants now, 52 under way, 6 of them phase 3. Scleroderma, Systemic · United States.

Enrollment
7th of 142
314 · median 34
Started
2023
with 10 others
Phase 3
12 of 165
3 open now
Primary completion
2027-01
later than 6 of 51 live
Registered
119th of 165
by date
Lead sponsor
3 of 165
AstraZeneca

Among the 165 studies in Scleroderma, Systemic with a site in United States, this one is the 7th largest by enrollment of the 142 interventional ones that give a count, is one of 11 that started in 2023, is one of 12 in phase 3, reaches primary completion later than 6 of the 51 other live ones, and was the 119th registered.

Scleroderma, Systemic

613 studies on the registry are indexed under Scleroderma, Systemic; 221 are open to participants now.

Browse Scleroderma, Systemic studies →

Open to participants now

40 of the 165 studies in Scleroderma, Systemic with a site in United States are open now. Recruiting first, the newest first:

35 more — sign in →

All 40 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 145 Scleroderma, Systemic studies recruiting now, 83 (57%) set no upper age limit and 49 (34%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 165 studies in Scleroderma, Systemic with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of treatment with subcutaneous anifrolumab versus placebo in adult participants with systemic sclerosis. The target population for this study includes patients who meet the 2013 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) classification for systemic sclerosis, either limited or diffuse cutaneous subsets, with a disease duration of less than 6 years from first non-Raynaud's phenomenon symptom.

Read the detailed description

This is a multicenter, randomized, double-blind, placebo-controlled, Phase III study to evaluate the efficacy and safety of anifrolumab in the treatment of adult participants with Systemic Sclerosis (SSc) who may be taking one or a combination of protocol-specified standard therapies. The use of one of the following standard immunosuppressant therapies is permitted at a stable dose, but not mandated: hydroxychloroquine, mycophenolate mofetil (MMF), mycophenolic acid or mycophenolate sodium (MPA/MPS), methotrexate, azathioprine, tacrolimus, and oral glucocorticoids. MMF or MPA/MPS, azathioprine, and methotrexate may be used in combination with hydroxychloroquine and/or low-dose oral glucocorticoids [≤ 10 mg/day].

Approximately 306 eligible participants will be randomized in a 1:1 ratio to receive either anifrolumab (or matching placebo) given subcutaneously once weekly for 52 weeks. The study will be stratified by the following factors:

  • Interstitial lung disease (ILD) (yes, no) at Week 0 (Day1);
  • MMF or MPA/MPS use (yes ,no) at Week 0 (Day 1); and
  • Disease duration, defined as the time from the first non-Raynaud's symptom attributable to SSc (\<18 months, ≥ 18 months) at Week 0 (Day 1)

Study treatment will be administered subcutaneously via an accessorized prefilled syringe by study staff or by the participant or carer, either in the clinic or at home, with most doses being administered at home. The study consists of 4 periods: a 6-week screening period, a 52-week, double-blind, placebo-controlled period, a 52-week open-label active treatment period, and a 12-week safety follow-up period. There are a total of 16 study visits with most visits in the treatment period occurring every 8 to 12 weeks. The periods are described below:

  • Screening Period: This may involve one or more visits to the study site.
  • Double Blind Treatment Period: Treatment Period when participants will receive once weekly injections of anifrolumab or matching placebo. Participation will involve in-clinic study visits at Weeks 0 (Day 1), 1, 4, 8*, 16, 24, 36, 48 and 52. *The visit at Week 8 may be either by telephone or in person.
  • Open Label Treatment Period: At Week 52, all participants will be given anifrolumab (subcutaneous) once weekly for 52 weeks (last dose at Week 103). Participation will involve in-clinic study visits at Weeks 52, 53*, 56, 64, 76. 88 and 104. *The visit at Week 53 may be either by telephone or in person.
  • Safety Follow-up Period: All participants will return to the clinic for a 12-week post treatment visit. This will occur post Double Blind Treatment Period (Week 52 or Double Blind Period early discontinuation) or post Open Label Treatment Period (Week 104 or Open Label Period early discontinuation).
03

Conditions studied

  • Systemic Sclerosis
  • Scleroderma

Keywords

  • Systemic Sclerosis (SSc)
  • Scleroderma
  • Anifrolumab
  • Limited
  • Diffuse
  • Cutaneous
  • Interstitial lung disease (ILD)
  • Autoimmune diseases
  • Immune system diseases
  • Immunosuppressants
  • Systemic Sclerosis interstitial lung disease (SSc- ILD)
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Adult patients from 18 to 70 years of age inclusive
  2. Systemic sclerosis according to 2013 ACR/EULAR classification criteria
  3. Limited or diffuse cutaneous subsets
  4. Systemic sclerosis disease duration within 6 years from first non-Raynaud's phenomenon manifestation at the time of signing the ICF
  5. Either HAQ-DI score ≥ 0.25 points or PtGA score ≥ 3 points
  6. mRSS > 10 with early disease or rapid progression as defined by the protocol
  7. mRSS ≥ 15 with disease duration ≥ 18 months and active disease as defined by the protocol
  8. Stable background therapies can be used including hydroxychloroquine, methotrexate, azathioprine, mycophenolate mofetil, mycophenolate sodium, mycophenolic acid, oral or tacrolimus
  9. Women of with a negative urine pregnancy test
  10. Uninvolved skin at injection sites

Key Exclusion Criteria:

  1. Anticentromere antibody seropositivity on central laboratory
  2. Severe cardiopulmonary disease as defined by the protocol
  3. History of systemic sclerosis renal crisis within past 12 months (estimated (eGFR) \< 45 mL/min/1.73m2)
  4. Overlap syndromes, systemic lupus erythematosus with anti-double-stranded deoxyribonucleic acid antibody seropositivity or anti-citrullinated protein antibodies-positive rheumatoid arthritis, or SSc mimics (eg, scleromyxedema, eosinophilic fasciitis)
  5. History of, or current, any other inflammatory diseases, eg, inflammatory bowel disease, skin disease, that, in the opinion of the investigator, could interfere with efficacy and safety assessments or require immunomodulatory therapy
  6. Evidence of moderately severe concurrent nervous system, renal, endocrine, hepatic (eg, underlying chronic liver disease [ A, B, C hepatic impairment]), or gastrointestinal disease (eg, clinical signs of malabsorption or needing parenteral nutrition) not related to SSc, as determined by the investigator
  7. Hematopoietic stem cell transplantation or solid organ/limb transplantation
  8. Any severe case of Herpes Zoster infection as defined by the protocol
  9. Known or a history of malignancy within 5 years, with exception of excised/cured local basal or squamous cell carcinoma of the skin or carcinoma in situ of the uterine cervix
  10. Major surgery within 8 weeks prior to and/or during study enrollment
  11. Known active current or history of recurrent infections
  12. Any condition that, in the opinion of the investigator or AstraZeneca, would interfere with the efficacy or safety evaluation of the study intervention or put participant at safety risk
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
314 participants (actual)

Study arms

  • Experimental
    Anifrolumab (subcutaneous weekly injection)

    Anifrolumab subcutaneous injection once weekly

    Combination Product: Anifrolumab (blinded) · Combination Product: Anifrolumab (unblinded, open label)

  • Placebo comparator
    matched placebo control (subcutaneous weekly injection)

    matched placebo control subcutaneous injection once weekly

    Drug: Placebo (blinded)

Interventions

  • Combination productAnifrolumab (blinded)

    Anifrolumab treatment delivered subcutaneously, once weekly for 52 weeks

    Also known as: Treatment arm (blinded)

  • DrugPlacebo (blinded)

    matched placebo delivered subcutaneously, once weekly for 52 weeks

    Also known as: Placebo arm (blinded)

  • At Week 52, all patients will receive Anifrolumab subcutaneously once weekly for 52 weeks

    Also known as: Treatment arm (not blinded)

06

What researchers measure

Primary outcomes

  1. Number of participants responding to treatment based on the Revised Composite Response Index in Systemic Sclerosis (CRISS-25)

    Number of participants meeting all the criteria: * Improvement in at least 2 components (≥5% increase for percent predicted Forced Vital Capacity (FVC) and/or≥25% decrease for Modified Rodnan Skin Score (mRSS), Health Assessment Questionnaire Disability Index (HAQ-DI), Patient Global Assessment (PtGA), Clinician Global Assessment (CGA) * Worsening in no more than one component (≥5% decrease percent predicted FVC and/or≥25% increase for mRSS, HAQ-DI, PtGA, CGA) * No significant SSc-related event as defined by: New scleroderma renal crisis New decline in percent predicted FVC≥15% in established interstitial lung disease or new percent predicted FVC below 80% predicted New onset of left ventricular failure requiring treatment New onset of pulmonary arterial hypertension requiring treatment Gastrointestinal dysmotility requiring enteral or parenteral nutrition Digital ischemia with gangrene, amputation, or hospitalization requiring treatment -Otherwise, a participant is a non-responder

    Time frame: at Week 52

Secondary outcomes

  1. Change from baseline in mRSS

    Change from baseline in mRSS score. The mRSS scoring ranges from 0 (normal) to 51 (severe).

    Time frame: at Week 52

  2. Number of patients with improvement in individual revised Composite Response Index in Systemic Sclerosis (CRISS-25)

    Number of participants who have improvements in the following improvement components, evaluated separately: * ≥ 5% increase in percent predicted Forced Vital Capacity (FVC) * ≥ 25% decrease in mRSS * ≥ 25% decrease in HAQ-DI * ≥25% decrease in PtGA * ≥25% decrease in CGA

    Time frame: at Week 52

  3. Change from baseline in chest computed tomography imaging

    Change from baseline in quantitative interstitial lung disease score

    Time frame: at Week 52

  4. Change from baseline in Scleroderma Skin Patient Reported Outcome

    Change from baseline in the Scleroderma Skin Patient Reported Outcome scores

    Time frame: at Week 52

  5. Change from baseline in FVC

    1. Change from baseline in FVC (ml) in patients with interstitial lung disease 2. Change from baseline in FVC (ml) in all patients

    Time frame: at Week 52

  6. Change from baseline in percent predicted FVC

    1. Change from baseline in percent predicted FVC in patients with interstitial lung disease 2. Change from baseline in percent predicted FVC in all patient

    Time frame: at Week 52

  7. Anifrolumab pharmacokinetic parameters in serum

    Anifrolumab serum concentrations will be summarised using descriptive statistics at each visit. Due to sparse pharmacokinetic sampling, the pharmacokinetic assessment will be primarily based on observed serum trough concentrations (Ctrough)

    Time frame: Weeks 4, 16, 24, 36, 52, 56, 76, and 104 to follow-up (max 116 weeks)

  8. Anifrolumab pharmacodynamics via changes in type I IFN 21-gene signature generated from blood

    Type I Interferon inducible gene signature will be assessed by a 21-gene assay in whole blood. The suppression of the type I IFN 21-gene signature will be showed as a percent of baseline through study completion, during both the double-blind treatment and open label periods.

    Time frame: Double-blind treatment period: pre-dose (Day 1) Weeks 4, 16, 24, 52; open-label period: weeks 56, 76 and 104

  9. Prevalence of anti-drug antibodies to Anifrolumab

    Anti-drug antibodies and titer determination in anti-drug antibody positive participants. The presence of neutralizing anti-drug antibodies will also be tested in all anti-drug positive samples.

    Time frame: Weeks 4, 16, 24, 36, 52, 56, 76, and 104 to follow-up (max 116 weeks)

  10. Incidence of adverse events

    Adverse events (non-serious, serious, and adverse event of special interest (AESI)) are assessed as variables of safety and tolerability of anifrolumab. The AESIs are non-opportunistic serious infections, opportunistic infections, malignancy, herpes zoster, Tuberculosis (TB) (including latent TB), injection site reactions, and major adverse cardiac events.

    Time frame: From screening to follow-up (max 126 weeks)

  11. Incidence of abnormal vital signs

    Change from baseline of pulse rate, blood pressure, respiration rate, and body temperature will be assessed by visit and treatment group including participants with treatment-emergent changes.

    Time frame: From screening to follow-up (max 126 weeks)

  12. Incidence of abnormal laboratory parameters

    Changes from baseline in haematology, clinical chemistry and lipid variables will be assessed by visit and treatment including participants with treatment-emergent changes.

    Time frame: From screening to follow-up (max 126 weeks)

  13. Incidence of abnormal ECG findings

    Observed values of heart rate, QRS duration, PR interval, RR interval and QT interval will be summarised by visit and treatment group including participants with clinically significant abnormal results.

    Time frame: From screening to end of treatment visit (max 110 weeks)

  14. Incidence of abnormal physical exam findings

    Changes from baseline in weight (kilograms) will be assessed by visit and treatment and medically significant changes from the screening physical examination will be recorded as adverse events.

    Time frame: From screening to follow-up (max 126 weeks)

  15. Number of subjects with suicidal ideation and behavior and suicide attempts via Columbia-Suicide Severity Rating Scale (C-SSRS)

    The C-SSRS is used to assess suicidal ideation, behavior, and suicide on a graded scale from 1 to 5. 1 indicates as low suicidal and 5 as high suicidal behavior.

    Time frame: From screening to follow-up (max 126 weeks)

  16. Total score of Personal Health Questionnaire Depression Scale-8 (PHQD-8)

    PHQ-8 is an 8-item self-report scale, all items are rated on a score of 0-3, for a total range of 0-24. PHQD-8 assesses symptoms of depression over the previous 2 weeks. Higher scores indicate more depressive symptoms.

    Time frame: From screening to follow-up (max 126 weeks)

07

Study locations

151 sites
  • Research Site
    Scottsdale, Arizona 85259, United States
  • Research Site
    Chula Vista, California 91910, United States
  • Research Site
    Los Angeles, California 90095, United States
  • Research Site
    Orange, California 92868, United States
  • Research Site
    Aurora, Colorado 80045, United States
  • Research Site
    New Haven, Connecticut 06519, United States
  • Research Site
    Washington D.C., District of Columbia 20007, United States
  • Research Site
    Boca Raton, Florida 33486, United States
  • Research Site
    Fort Lauderdale, Florida 33309, United States
  • Research Site
    Gainesville, Florida 32603, United States
  • Research Site
    Jacksonville, Florida 32216, United States
  • Research Site
    Margate, Florida 33063, United States
  • Research Site
    South Miami, Florida 33143, United States
  • Research Site
    Tamarac, Florida 33321, United States
  • Research Site
    Chicago, Illinois 60611, United States
  • Research Site
    Kansas City, Kansas 66160, United States
  • Research Site
    New Orleans, Louisiana 70121, United States
  • Research Site
    Baltimore, Maryland 21224, United States
  • Research Site
    Ann Arbor, Michigan 48109, United States
  • Research Site
    Rochester, Minnesota 55905, United States
  • Research Site
    Babylon, New York 11702, United States
  • Research Site
    New York, New York 10032, United States
  • Research Site
    Cincinnati, Ohio 45219, United States
  • Research Site
    Pittsburgh, Pennsylvania 15213, United States
  • Research Site
    Allen, Texas 75013, United States
  • Research Site
    Houston, Texas 77030, United States
  • Research Site
    Graz, 8036, Austria
  • Research Site
    Innsbruck, 6020, Austria
  • Research Site
    Vienna, 1090, Austria
  • Research Site
    Ghent, B-9000, Belgium
  • Research Site
    Leuven, 3000, Belgium
  • Research Site
    Calgary, Alberta T2N 4Z6, Canada
  • Research Site
    Toronto, Ontario M5T 3L9, Canada
  • Research Site
    Montreal, Quebec H3T 1E2, Canada
  • Research Site
    Montreal, Quebec H4J 1C5, Canada
  • Research Site
    Québec, Quebec G1V 4K5, Canada
  • Research Site
    Beijing, 100191, China
  • Research Site
    Beijing, CN-100730, China
  • Research Site
    Guangzhou, 510100, China
  • Research Site
    Guangzhou, 510530, China
  • Research Site
    Hangzhou, 310014, China
  • Research Site
    Lanzhou, 730000, China
  • Research Site
    Shanghai, 200032, China
  • Research Site
    Shanghai, 201210, China
  • Research Site
    Tianjin, 300050, China
  • Research Site
    Bordeaux, 33076, France
  • Research Site
    Brest, 29609, France
  • Research Site
    Paris, 75014, France
  • Research Site
    Paris, 75020, France
  • Research Site
    Paris, 75679, France
  • Research Site
    Rennes, 35033, France
  • Research Site
    Strasbourg, 67098, France
  • Research Site
    Toulouse, 31059, France
  • Research Site
    Freiburg im Breisgau, 79106, Germany
  • Research Site
    Mainz, 55131, Germany
  • Research Site
    Minden, 32429, Germany
  • Research Site
    Münster, 48149, Germany
  • Research Site
    Tübingen, 72076, Germany
  • Research Site
    Budapest, 1023, Hungary
  • Research Site
    Budapest, 1027, Hungary
  • Research Site
    Budapest, 1138, Hungary
  • Research Site
    Debrecen, 4032, Hungary
  • Research Site
    Pécs, 7632, Hungary
  • Research Site
    Szeged, 6725, Hungary
  • Research Site
    Ahmedabad, 380006, India
  • Research Site
    Delhi, 110060, India
  • Research Site
    Gurugram, 122001, India
  • Research Site
    Hyderabad, 500082, India
  • Research Site
    Kolkata, 700020, India
  • Research Site
    Mumbai, 400053, India
  • Research Site
    Mysuru, 570004, India
  • Research Site
    New Delhi, 11029, India
  • Research Site
    Pune, 411001, India
  • Research Site
    Secunderabad, 500003, India
  • Research Site
    Afula, 18101, Israel
  • Research Site
    Haifa, 31048, Israel
  • Research Site
    Haifa, 31096, Israel
  • Research Site
    Jerusalem, 00000, Israel
  • Research Site
    Kfar Saba, 4428164, Israel
  • Research Site
    Ramat Gan, 52621, Israel
  • Research Site
    Ancona, 60126, Italy
  • Research Site
    Brescia, 25123, Italy
  • Research Site
    Cona, 44124, Italy
  • Research Site
    Milan, 20122, Italy
  • Research Site
    Padova, 35128, Italy
  • Research Site
    Roma, 00128, Italy
  • Research Site
    Roma, 00168, Italy
  • Research Site
    Roma, 161, Italy
  • Research Site
    Bunkyō City, 113-8603, Japan
  • Research Site
    Fukuoka, 812-8582, Japan
  • Research Site
    Iruma-Gun, 350-0495, Japan
  • Research Site
    Kanazawa, 920-8641, Japan
  • Research Site
    Maebashi, 371-8511, Japan
  • Research Site
    Nagasaki, 852-8501, Japan
  • Research Site
    Nagoya, 457-0866, Japan
  • Research Site
    Sapporo, 060-8638, Japan
  • Research Site
    Sendai, 980-8574, Japan
  • Research Site
    Shinjuku-ku, 160-8582, Japan
  • Research Site
    Suita-shi, 565-0871, Japan
  • Research Site
    Takatsuki-shi, 569-8686, Japan

Showing the first 100 of 151 sites across 23 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Lescoat A, Lecureur V, Gudjonsson JE, Khanna D. Systemic sclerosis: pathogenic mechanisms and their implications for treatment. Semin Immunopathol. 2025 Nov 11;47(1):39. doi: 10.1007/s00281-025-01065-6. PubMed 41217519 ↗

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AstraZeneca disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AstraZeneca group of companies sponsored clinical trials are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. The timelines vary per request and can take up to a year upon full submission of the request for analysis, decision, anonymisation and sharing of the requested data or documents. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved, AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2023 (actual). Primary completion is estimated for Jan 2027, 37 months after the start.

Of 17 phase 3 interventional studies under Scleroderma, Systemic, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 54. This study's planned 37 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 2, 2023
First posted
Jun 29, 2023
StartActual
Nov 8, 2023
Primary completionEst.
Jan 6, 2027
CompletionEst.
Apr 5, 2028
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added
Show site
  • Research Site · Paris, France
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    1 site added
    Show site
    • Research Site · Paris, France
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05925803
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jun 29, 2023
Start date
Nov 8, 2023
Primary completion
Jan 6, 2027 (estimated)
Completion
Apr 5, 2028 (estimated)
Last update
Nov 16, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anifrolumab

Start the discussion